KEYTRUDA® (Pembrolizumab)

The FDA on October 2, 2015 granted accelerated approval to KEYTRUDA® for the treatment of patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors express Programmed Death Ligand 1 (PD-L1) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. KEYTRUDA® Injection is a product of Merck Sharp and Dohme Corporation.